1 芮建中.群体药动学药效学原理及应用进展[J].国外医学·药学分册,1995;22:277-82 2 胡敏,张静华,孙鹤,施孝金,俞丽云.非线性混合效应模型法估算门诊癫痫患者丙戊酸的相对清除率[J].中国临床药学杂志,2000;9:33 3 叶祥枝.丙戊酸钠缓释片治疗儿童癫痫的疗效及血药浓度[J].中国新药与临床杂志,1998;17:33-4 4 瞿治平.癫痫发作分类及药物临床疗效评定标准的建议(草案)[J].神经精神疾病杂志,1980;6:248 5 陈刚,卢建丰.一步法估算茶碱药动学参数[J].中国药学杂杂志,1991;26:659-61 6 芮建中,杨友春,王亦流,陈刚.硫酸镁治疗妊娠高血压综合征的群体药动学-药效学[J].药学学报,1996;31:81-5 7 Lee H,Kimko HC,Rogge M,Wang D,Nestorov I,Peck CC.Population pharmacokinetic and pharmacodynamic modeling of Etanercept using logistic regression analysis[J].Clin Pharmacol Ther,2003;73:348-65 8 Xie R,Mathijssen RH,Sparreboom A,Verweij J,Karlsson MO.Clinical pharmacokinetics of Irinotecan and its metabolites in re-lationwith diarrhea[J].Clin Pharmacol Ther,2002;72:265-75 9 Jen J,Laughlin M,Chung C,Heft S,Affrime MB,Gupta SK,et al.Ribavirin dosing in chronic hepatitis C:Application of popu-lation pharmacokinetic-pharmacodynamic models[J].Clin Phar-macol Ther,2002;72:349-61 10 Mould D,Chapelsky M,Aluri J,Swagzdis J,Samuels R,Granett J.A population pharmacokinetic -pharmacodynamic and logistic regression of lotrafiban in patients[J].Clin Pharmacol Ther,2001;69:210-22 11 Mould DR,HolfordNH,Schellens JH,Beijnen JH,Hutson PR,Rosing H,et al.Population pharmacokinetic and adverse event analysis of topotecan in patientswith solid tumors[J].Clin Phar-macol Ther,2002;71:334-48 12 Beal SL.Validation of population model.E-mail to NONMEM users participants[J].February 2,1994 |